Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company. It develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR, an adjunct therapy for the treatment of partial seizures; and Trokendi XR, an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its psychiatry pipeline portfolio comprises SPN-810 (Phase IIb completed) for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); SPN-812 (Phase IIa completed) for the treatment of ADHD; and SPN-809 that has an active IND for the treatment of depression. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). Supernus is headquartered in Rockville, Maryland, the US.